TrialThe Journal of infectious diseases2011

Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.

Viktor Dahl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.